Purpose To evaluate the efficacy and safety of erlotinib in advanced non-small-cell lung
cancer after failure of gefitinib treatment. Patients and methods Patients with advanced or …

Background Gefitinib and erlotinib are two orally active epidermal growth factor receptor
tyrosine kinase inhibitors used in the treatment of advanced non-small cell lung cancer …

Purpose Recent studies have demonstrated that erlotinib therapy may be considered an
option for patients with advanced non-small-cell lung cancer who experienced disease …

Background Several clinical trials showed that erlotinib was effective after the failure of
gefitinib in advanced non-small cell lung cancer (NSCLC). The aim of this study was to …

Background: Both gefitinib and erlotinib are reversible epidermal growth factor receptor
tyrosine kinase inhibitors, but they have somewhat different pharmacological properties. We …

Phase II Study of Erlotinib in Advanced Non–Small-Cell Lung Cancer After Failure of Gefitinib
Page 1 Phase II Study of Erlotinib in Advanced Non–Small-Cell Lung Cancer After Failure of …

Background: Erlotinib and gefitinib are epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs). They have the same mechanism of action and very similar side …

PURPOSE: The use of erlotinib after gefitinib failure in patients with non-small cell lung
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …

Purpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer
(NSCLC). Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR …

BACKGROUND: Gefitinib and erlotinib are commonly used for salvage therapy in patients
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …